Theragent and Pluristyx Announce Collaboration to Accelerate Development of iPSC-based Therapies
Wednesday, May 08, 2024
Theragent Inc., a prominent Contract Development and Manufacturing Organization (CDMO) specializing in advancing cutting-edge cell- and tissue-based therapies, has announced a significant collaboration with Pluristyx, Inc., a pioneering biotech firm focusing on induced Pluripotent Stem Cell (iPSC) products. This partnership is aimed at providing a seamless pathway for therapeutic developers, starting from iPSC derivation to the commercial production of iPSC-derived drug products.
Under the terms of the collaboration, Pluristyx's iPSC platform, featuring licenses for iPSC derivation and innovative technologies like the FailSafe® functional suicide switch and iACT Stealth Cells® immune evasion technology, will be utilized for early-stage programs. Later, these processes will transition to Theragent for Good Manufacturing Practice (GMP) processing, including scale-up and the production of clinical- to commercial-scale iPSC-derived therapies at their manufacturing facility in Arcadia, CA.
Pluristyx, expressed excitement about deepening the partnership with Theragent, aiming to establish a synchronized platform that combines clinical-grade iPSC lines with Theragent's CGMP manufacturing capabilities. This integrated approach, he believes, will pave a clear and efficient path from research to commercialization for the next generation of iPSC-derived treatments.
Theragent, echoed this sentiment, emphasizing the tremendous therapeutic potential of iPSCs. Dr. Yen highlighted the strategic importance of partnering with a recognized iPSC technical leader like Pluristyx. Leveraging Theragent's expertise in stem cell technologies and their state-of-the-art manufacturing facility, Dr. Yen underscored the partnership's ability to ensure 'right first time, on time' tech transfer and production, ultimately saving clients time and money while mitigating risks associated with clinical programs.
Source: prnewswire.com
